Target General Information
Target ID T10877 Target Info
Target Name Cyclic ADP-ribose hydrolase 1 (CD38)
Synonyms cADPr hydrolase 1; T10; Cyclic ADPribose hydrolase 1; ADPribosyl cyclase 1; ADPRC 1; ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1; ADP-ribosyl cyclase 1; 2'-phospho-cyclic-ADP-ribose transferase; 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase; 2'-phospho-ADP-ribosyl cyclase
Target Type Successful Target
Gene Name CD38
Biochemical Class Glycosylase
UniProt ID
Targeted Antigens of CAR-T Cell Therapy
CAR T-Cell Therapy Drug(s) 4SCAR19 and 4SCAR38 Drug Info Phase 1/2 B-cell lymphoma [1]
Anti-CD38 CAR-T cells Drug Info Phase 1/2 Multiple myeloma [2]
CD38 and BCMA CAR-T Cells Drug Info Phase 1/2 Multiple myeloma [3]
CD38 CAR T cells Drug Info Phase 1/2 Multiple myeloma [4]
CD38 CAR-T Cell Drug Info Phase 1/2 Acute lymphoblastic leukaemia [5]
CD38-specific gene-engineered T cells Drug Info Phase 1/2 Acute myeloid leukaemia [6]
Anti-CD38 CAR-T cells Drug Info Phase 1 Multiple myeloma [7]
CART-38 cells Drug Info Phase 1 Myelodysplastic syndrome [8]
CAR-T cells targeting CD38 Drug Info Clinical trial Multiple myeloma [9]
CAR-T cells targeting CD38 Drug Info Preclinical Acute myeloid leukaemia [10]
References
REF 1 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
REF 2 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
REF 3 ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
REF 4 ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
REF 5 ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy
REF 6 ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
REF 7 ClinicalTrials.gov (NCT03464916) Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
REF 8 ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
REF 9 ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
REF 10 ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.